Valeria Tosello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2184093/publications.pdf

Version: 2024-02-01

48 papers	3,438 citations	236925 25 h-index	254184 43 g-index
48 all docs	48 docs citations	48 times ranked	6131 citing authors

#	Article	IF	Citations
1	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. Leukemia, 2021, 35, 984-1000.	7.2	12
2	Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia. International Journal of Molecular Sciences, 2021, 22, 8738.	4.1	11
3	miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia. Cells, 2020, 9, 1726.	4.1	17
4	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	13.2	32
5	WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103, 266-277.	3.5	21
6	Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death. Oncotarget, 2016, 7, 45715-45729.	1.8	16
7	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	30.7	180
8	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
9	DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Blood, 2014, 124, 365-365.	1.4	0
10	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	16.8	220
11	The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Therapeutic Advances in Hematology, 2013, 4, 199-210.	2.5	76
12	Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine, 2013, 19, 368-371.	30.7	304
13	Targeting Nonclassical Oncogenes for Therapy in T-ALL. Cancer Cell, 2012, 21, 459-472.	16.8	84
14	Therapeutic Utility of PI3KÎ³ Inhibition in Leukemogenesis and Tumor Cell Survival. Blood, 2012, 120, 1492-1492.	1.4	1
15	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. Blood, 2012, 120, 285-285.	1.4	5
16	ETV6 mutations in early immature human T cell leukemias. Journal of Experimental Medicine, 2011, 208, 2571-2579.	8.5	184
17	The TLX1 oncogene drives aneuploidy in T cell transformation. Nature Medicine, 2010, 16, 1321-1327.	30.7	139
18	Absence of Biallelic TCRÎ³ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	1.6	93

#	Article	IF	Citations
19	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	1.4	0
20	Identification of NOTCH1-Controlled Transcriptional Programs In Human T-Cell Development. Blood, 2010, 116, 2495-2495.	1.4	0
21	Differential expression of constitutive and inducible proteasome subunits in human monocyteâ€derived DC differentiated in the presence of IFNâ€Î± or ILâ€4. European Journal of Immunology, 2009, 39, 56-66.	2.9	24
22	Î³-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine, 2009, 15, 50-58.	30.7	417
23	WT1 mutations in T-ALL. Blood, 2009, 114, 1038-1045.	1.4	111
24	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. Blood, 2009, 114, 142-142.	1.4	8
25	Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL.. Blood, 2009, 114, 676-676.	1.4	0
26	Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clinical Immunology, 2008, 126, 291-302.	3.2	46
27	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-Î± Antitumor Effects. Cancer Research, 2008, 68, 5658-5668.	0.9	121
28	NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood, 2008, 112, 733-740.	1.4	116
29	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. Blood, 2008, 112, 298-298.	1.4	3
30	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8947-8952.	7.1	275
31	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. Cancer Research, 2007, 67, 8605-8614.	0.9	41
32	Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clinical Immunology, 2007, 122, 163-172.	3.2	16
33	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.. Blood, 2007, 110, 151-151.	1.4	4
34	A Novel Class of Activating Mutations in NOTCH1 in T-ALL.. Blood, 2007, 110, 694-694.	1.4	5
35	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4216-4221.	7.1	113
36	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38

#	Article	IF	Citations
37	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. British Journal of Haematology, 2005, 130, 878-889.	2.5	11
38	Interferon-Î± Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, 16, 957-970.	2.7	34
39	Interferon- Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, .	2.7	0
40	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Experimental Cell Research, 2003, 287, 28-38.	2.6	24
41	CD8+Î±Î²+T Cells That Lack Surface CD5 Antigen Expression Are a Major Lymphotactin (XCL1) Source in Peripheral Blood Lymphocytes. Journal of Immunology, 2003, 171, 4528-4538.	0.8	21
42	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. Journal of Immunology, 2002, 169, 4017-4024.	0.8	42
43	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. Gene, 2002, 283, 199-208.	2.2	11
44	Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Research, 2002, 62, 6099-107.	0.9	41
45	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 2001, 98, 3607-3617.	1.4	28
46	Alteration in Calcium Handling at the Subcellular Level inmdx Myotubes. Journal of Biological Chemistry, 2001, 276, 4647-4651.	3.4	136
47	Recombinant aequorin and green fluorescent protein as valuable tools in the study of cell signalling. Biochemical Journal, 2001, 355, 1.	3.7	92
48	Recombinant aequorin as tool for monitoring calcium concentration in subcellular compartments. Methods in Enzymology, 2000, 327, 440-456.	1.0	28